| |
| Home > HUCPVC Technologies |
| |
|
| |
| HUCPVCs are a type of stem cell – the “mesenchymal stromal cells” (MSC) – also called mesenchymal stem cells- cells which have many varied and special properties. MSCs give rise to specialized cells in the body that make the musculo-skeletal system (bone, cartilage, fibrous tissue and muscle). MSCs have also been shown to have very special immune-regulatory functions and have been used to treat immune and inflammatory diseases. |
| |
| HUCPVCs = Human Umbilical Cord Perivascular Cells |
| |
| HUCPVCs, extracted from umbilical cord tissue, are the richest source of MSCs ever discovered. They can rapidly provide clinically relevant doses for stem cell therapy. |
| |
The
HUCPVC Advantage:
- A rich source of non-controversial stem cells
- Adult stem cells – not embryonic
- Derived from cord tissue which is discarded at birth
- Multipotential: shown to produce all five connective tissues - bone, cartilage, muscle, fibrous tissue and fat.
- Shown in, in vitro tests, to have the immuno-regulatory capacity as other MSCs
- Fast proliferation, enabling rapid attainment of clinically-relevant doses of cells
- Can be easily frozen until required for use
|
|
|
 |
 |
|
| |
| |
| The use of HUCPVCs in medical treatment as a therapy for immune and inflammatory diseases, or for the regeneration of the musculo-skeletal system. Clinical trials are in preparation to launch HUCPVC Therapy™ into the commercial medical arena. |
| |
| |
| Focuses on the collection and cryogenic storage of the cells for a family, at the birth of their child. Cryogenic storage provides a stabilized environment for the cells to be kept in liquid nitrogen at a constant temperature of -196˚C, proven to maintain cell functionality after thaw for future clinical use. |
| |
| |
TRT discovered this special population of ethically non-controversial stem cells in the tissue immediately surrounding the blood vessels of the human umbilical cord. These are different from cells taken from the placenta or Wharton’s Jelly.
HUCPVCs are true multipotent mesenchymal stem cells.
HUCPVCs are also quite distinct from the blood stem cells which
circulate in the blood itself. Blood stem cells, also
taken from the umbilical cord, have none of the unique
properties of MSCs. |
| |
| |
| MSCs are already being employed in clinical
medicine to treat diseases such as Crohn’s disease, heart
attack and bone diseases. MSCs are currently harvested
from bone marrow, and the supply of cells from this source
is limited. In comparison,the umbilical cord is
a 10,000 times richer source of these cells. MSC research
also suggests that MSCs may be used to treat many other
immune, inflammatory and degenerative diseases such as
Rheumatoid Arthritis, Multiple Sclerosis, or liver conditions.
Alternatively, they may be used together with blood stem
cells to reconstitute a patient’s bone marrow. In addition,
they can be used to regenerate the musculo-skeletal tissues
of the body – bone, cartilage, muscle, ligaments and tendons. |
| |
| |
| HUCPVCs are a specialized source of MSCs found in the Umbilical Cord Tissue and stored until needed for therapy, whereas BM is taken directly from the patients own bone marrow. As the MSC number in BM is low, the cells have to be grown for several weeks before being ready for therapeutic use. |
| |
| With HUCPVCs the source of cells is extracted
from the umbilical cord after the full term birth of a
new born baby, providing access to an extremely rich source
of MSCs. HUCPVCs also grow very quickly – this translates
into a shorter turnaround time for therapeutic doses of
cells. Independent studies at Princess Margaret Hospital
in Toronto, and at the
National Institutes of Health in Bethesda, USA, have shown that HUCPVCs are bio-equivalent to BM-derived MSCs. |
| |
| As the umbilical cord is currently
discarded as medical waste after the full
term birth of a baby, storing this new
source of stem cells makes sense as it does
not compromise the health of either mother
or baby.
|
| |
